Digital PCR applications for the diagnosis and management of infection in critical care medicine

• Published in: Critical care (London, England) Vol. 26; no. 1; p. 63
• Main Authors: Merino, Irene, de la Fuente, Amanda, Domínguez-Gil, Marta, Eiros, José María, Tedim, Ana P, Bermejo-Martín, Jesús F
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21-03-2022; BioMed Central; BMC
• Subjects: Antimicrobial agents; Bacterial pneumonia; Care and treatment; Community-acquired infections; Coronaviruses; COVID-19; COVID-19 - diagnosis; Critical Care; Critical care medicine; Critically ill patients; Diagnosis; Digital PCR; Drug resistance; Evaluation; Host response; Humans; Identification; Infection diagnosis; Infectious diseases; Intensive care; Management; Medical diagnosis; Medical prognosis; Medicine; Methods; Microorganisms; Nosocomial infections; Pandemics; Pathogens; Patients; Pneumonia; Polymerase chain reaction; Prognosis and treatment guidance; Real-Time Polymerase Chain Reaction - methods; Reproducibility of Results; Review; Risk factors; Sepsis; Technology application; Ventilators; Spain; Host response; Digital PCR; Prognosis and treatment guidance; Infection diagnosis; Critically ill patients
• ISSN: 1364-8535; 1466-609X; 1364-8535; 1366-609X
• DOI: 10.1186/s13054-022-03948-8

Infection (either community acquired or nosocomial) is a major cause of morbidity and mortality in critical care medicine. Sepsis is present in up to 30% of all ICU patients. A large fraction of sepsis cases is driven by severe community acquired pneumonia (sCAP), which incidence has dramatically increased during COVID-19 pandemics. A frequent complication of ICU patients is ventilator associated pneumonia (VAP), which affects 10-25% of all ventilated patients, and bloodstream infections (BSIs), affecting about 10% of patients. Management of these severe infections poses several challenges, including early diagnosis, severity stratification, prognosis assessment or treatment guidance. Digital PCR (dPCR) is a next-generation PCR method that offers a number of technical advantages to face these challenges: it is less affected than real time PCR by the presence of PCR inhibitors leading to higher sensitivity. In addition, dPCR offers high reproducibility, and provides absolute quantification without the need for a standard curve. In this article we reviewed the existing evidence on the applications of dPCR to the management of infection in critical care medicine. We included thirty-two articles involving critically ill patients. Twenty-three articles focused on the amplification of microbial genes: (1) four articles approached bacterial identification in blood or plasma; (2) one article used dPCR for fungal identification in blood; (3) another article focused on bacterial and fungal identification in other clinical samples; (4) three articles used dPCR for viral identification; (5) twelve articles quantified microbial burden by dPCR to assess severity, prognosis and treatment guidance; (6) two articles used dPCR to determine microbial ecology in ICU patients. The remaining nine articles used dPCR to profile host responses to infection, two of them for severity stratification in sepsis, four focused to improve diagnosis of this disease, one for detecting sCAP, one for detecting VAP, and finally one aimed to predict progression of COVID-19. This review evidences the potential of dPCR as a useful tool that could contribute to improve the detection and clinical management of infection in critical care medicine.